Protein C Deficiency
1
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
TakedaTOKYO, Japan
2 programs1
Protein C ConcentratePhase 2/31 trial
Protein C ConcentrateN/A3 trials
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TakedaProtein C Concentrate
TakedaProtein C Concentrate
TakedaProtein C Concentrate
TakedaProtein C Concentrate
Clinical Trials (4)
Total enrollment: 79 patients across 4 trials
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
Start: Aug 2003Est. completion: Mar 200518 patients
Phase 2/3Completed
A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants With Congenital Protein C Deficiency
Start: Sep 2024Est. completion: Jun 20307 patients
N/ARecruiting
Ceprotin Treatment Registry
Start: Jun 2010Est. completion: Jun 201543 patients
N/ACompleted
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
Start: Jun 2005Est. completion: Dec 200511 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 79 patients
1 companies competing in this space